YaoGeJu

Company directoryChina company filings

Aurisco Pharmaceutical Co., Ltd.

As of 18 November 2026, for the company name Aurisco Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 4 active records with this name as holder; 15 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

6 acceptance records as first applicant, grouped into 4 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Abiraterone Acetate Tablets 1 records · Latest accepted 2025/11/14

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503962Generic2025/11/14Aurisco Pharmaceutical Co., Ltd.CDE ↗
Dydrogesterone Tablets 2 records · Latest accepted 2025/09/25

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2501904Supplement2025/09/25Aurisco Pharmaceutical Co., Ltd.; Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
CYHS2102225Generic2021/12/20Aurisco Pharmaceutical Co., Ltd.; Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Dolutegravir Sodium Tablets 1 records · Latest accepted 2025/04/24

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500817Supplement2025/04/24Aurisco Pharmaceutical Co., Ltd.; Jiangsu He Chen Pharma Co., Ltd. romanizedCDE ↗
Enzalutamide Tablets 2 records · Latest accepted 2024/08/09

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402539Generic2024/08/09Aurisco Pharmaceutical Co., Ltd.; Jiangsu Xuan Tai Pharma Co., Ltd. romanizedCDE ↗
CYHS2402538Generic2024/08/09Aurisco Pharmaceutical Co., Ltd.; Jiangsu Xuan Tai Pharma Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

1 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Abiraterone Acetate Tablets CYHS2503962Generic2025/11/14Aurisco Pharmaceutical Co., Ltd.CDE ↗

Catalogue holder records

4 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Dolutegravir Sodium TabletsAurisco Pharmaceutical Co., Ltd.Jiangsu He Chen Pharma Co., Ltd. romanized国药准字H202642252026/05/07Generic approved under the new chemical-drug registration classificationCDE ↗
Enzalutamide TabletsAurisco Pharmaceutical Co., Ltd.Jiangsu Xuan Tai Pharma Co., Ltd. romanized国药准字H202635532026/03/10Generic approved under the new chemical-drug registration classificationCDE ↗
Enzalutamide TabletsAurisco Pharmaceutical Co., Ltd.Jiangsu Xuan Tai Pharma Co., Ltd. romanized国药准字H202635522026/03/10Generic approved under the new chemical-drug registration classificationCDE ↗
Dydrogesterone TabletsAurisco Pharmaceutical Co., Ltd.Yangzhou Aurisco Pharmaceutical Co.,Ltd.国药准字H202337692023/06/21Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

15 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
布地奈德 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20250000390A2026/10/14CDE ↗
非奈利酮 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20250000120A2026/07/21CDE ↗
瑞卢戈利 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20240001152I2024/11/12CDE ↗
依普利酮 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20240001120A2026/10/09CDE ↗
阿帕他胺 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20240000148A2026/03/26CDE ↗
倍他米松 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20230000658A2026/10/30CDE ↗
糠酸莫米松 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20220001115A2024/06/28CDE ↗
糠酸氟替卡松 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20200001122A2025/12/17CDE ↗
恩扎卢胺 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20200000588A2025/07/28CDE ↗
丙酸氟替卡松 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20190007020A2022/10/28CDE ↗
富马酸丙酚替诺福韦 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20190000895A2023/07/28CDE ↗
醋酸阿比特龙 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20190000640A2026/02/13CDE ↗
普瑞巴林 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20190000368A2026/08/14CDE ↗
苯磺贝他斯汀 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20180001606A2026/08/14CDE ↗
富马酸替诺福韦二吡呋酯 · No verified English nameAurisco Pharmaceutical Co., Ltd.Y20170001514A2023/11/10CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

2 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
DIP-1018胶囊 · No verified English name CXHL2600866New drug2026/07/17Zhejiang University romanized; Zhejiang University Jin Hua Research Institute romanized; Name not romanized; Aurisco Pharmaceutical Co., Ltd.CDE ↗
DIP-1018胶囊 · No verified English name CXHL2600865New drug2026/07/17Zhejiang University romanized; Zhejiang University Jin Hua Research Institute romanized; Name not romanized; Aurisco Pharmaceutical Co., Ltd.CDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.